(Q47279577)

13 January 2018

title

High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. (English)

1 reference

13 January 2018

recurrent hepatocellular carcinoma

main subject

liver transplantation

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

4

1 reference

13 January 2018

author name string

Katharina Staufer

1

1 reference

13 January 2018

Lutz Fischer

2

1 reference

13 January 2018

Barbara Seegers

3

1 reference

13 January 2018

Bjoern Nashan

5

1 reference

13 January 2018

Martina Sterneck

6

1 reference

13 January 2018

publication date

6 August 2012

1 reference

13 January 2018

published in

Transplant International

1 reference

13 January 2018

volume

25

1 reference

13 January 2018

page(s)

1158-1164

1 reference

13 January 2018

issue

11

1 reference

13 January 2018

Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Treatment of recurrent hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Immunosuppression and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Management of hepatocellular carcinoma recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Sorafenib for recurrent hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Sorafenib-induced liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01540.X

10.1111/J.1432-2277.2012.01540.X

21 January 2018

Identifiers

DOI

1 reference

13 January 2018

release_qs22vnrxrnffdf3k2p72c6ul3y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qs22vnrxrnffdf3k2p72c6ul3y

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22882364

1 reference

13 January 2018